Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMG901 Phase 1 Study in Advanced Solid Tumors
NCT04805307Phase 1Completed
- Sponsor
- Keymed Biosciences
- Start
- Dec 2020
- Primary completion
- Apr 2024
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of sonesitatug vedotin in solid tumor (advanced stage), gastric cancer (GC), pancreatic cancer (PC) and 1 more (3 arms), sponsored by Keymed Biosciences. Primary endpoints: Incidence of adverse events, Occurrence of Dose-limiting toxicity and 3 more. Started Dec 2020; status: completed.
02
Drugs
sonesitatug vedotin
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)pancreatic cancer (PC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04805307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04805307.